The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

The management of RA, SpA, psoriasis and inflammatory bowel disease has significantly improved over the last decade with the addition of tumour necrosis factor inhibitors (anti-TNFs) to the therapeutic armamentarium. Immunogenicity in response to monoclonal antibody therapies (anti-drug antibodies)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jani, Meghna, Barton, Anne, Warren, Richard B., Griffiths, Christopher E. M., Chinoy, Hector
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894670/
https://www.ncbi.nlm.nih.gov/pubmed/23946436
http://dx.doi.org/10.1093/rheumatology/ket260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894670/
https://www.ncbi.nlm.nih.gov/pubmed/23946436
http://dx.doi.org/10.1093/rheumatology/ket260

Ejemplares similares